Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2013 Apr 25;12(7):1180–1189. doi: 10.1158/1535-7163.MCT-12-1176-T

Figure 7. Antitumor activity of SEN461 in a DBTRG xenograft tumor model in vivo.

Figure 7

DBTRG cells were injected s.c. into CD-1 nude mice on day 0 and SEN461 p.o. dosing started on day 28. Treatment groups (10 mice per group) were 30 mg/kg twice a day from day 28 to 41, 100 mg/kg/day daily from day 28 to 41 and 500 mg/kg/day once weekly on day 28 and 34. Tumor volume was followed over time until day 79 (37 days after the end of the treatment).